romosozumab
Evenity (romosozumab) is a sclerostin inhibitor from Amgen. Given as monthly injections for up to 12 months, it builds new bone and also slows bone breakdown, reducing fracture risk in postmenopausal women with severe osteoporosis.
This page is based on FDA prescribing information and the EMA medicine record for romosozumab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Bone is a living scaffold that is constantly rebuilt. Sclerostin is a brake signal that tells bone-building cells to slow down. Romosozumab blocks that brake, so the builders get back to work — laying down fresh, strong bone faster than the body breaks it down.
In simple terms
Romosozumab is an antibody that targets a protein called sclerostin, which normally holds back bone formation. By blocking sclerostin, the medicine stimulates the cells that build new bone (osteoblasts) and, to a lesser extent, reduces the activity of cells that break bone down. The result is stronger, denser bone and a lower chance of fractures. Treatment is limited to 12 monthly doses because the bone-building effect fades after that; afterward, another medicine is usually given to preserve the gains.
In depth
Romosozumab is a recombinant humanized IgG2 monoclonal antibody that binds sclerostin, a negative regulator of the Wnt signaling pathway. Sclerostin, secreted primarily by osteocytes, inhibits canonical Wnt/β-catenin signaling, suppressing osteoblast differentiation and activity. By neutralizing sclerostin, romosozumab restores Wnt pathway activity, increasing osteoblastic bone formation and, to a lesser extent, decreasing osteoclastic bone resorption through altered OPG/RANKL balance. The dual effect increases trabecular and cortical bone mass and improves bone structure and strength, reducing fracture risk. The anabolic effect wanes after 12 monthly doses as compensatory mechanisms upregulate sclerostin expression.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
Bone is a living scaffold that is constantly rebuilt.
- Romosozumab is an antibody that targets a protein called sclerostin, which normally holds back bone formation.
- Sclerostin is a brake signal that tells bone-building cells to slow down.
- By blocking sclerostin, the medicine stimulates the cells that build new bone (osteoblasts) and, to a lesser extent, reduces the activity of cells that break bone down.
- Treatment is limited to 12 monthly doses because the bone-building effect fades after that; afterward, another medicine is usually given to preserve the gains.
Target: Sclerostin
A negative regulator of bone formation secreted by osteocytes; it inhibits Wnt signaling and suppresses osteoblast development and function. Blocking it releases the brake on new bone building.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
Approved uses in European Union
EMA- Treatment of severe osteoporosis in postmenopausal women at high risk of fracture
Official sources
The statements on this page trace back to these records.
- U.S. Food and Drug Administration: romosozumab prescribing information
U.S. Food and Drug Administration
- Evenity (romosozumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Evenity (romosozumab) prescribing information
DailyMed, U.S. National Library of Medicine
- National Cancer Institute: romosozumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.